KAYO-1732

About KayoThera

Kayothera is developing a novel class of oral small molecule drugs targeting the retinoid nuclear receptor pathway, a clinically validated but previously undrugged driver of adverse metabolic and oncological outcomes. Its lead program, KAYO-1732, is a development candidate for type 2 diabetes and cardiometabolic disease, with additional programs in obesity (KAYO-2000) and male contraception (KAYO-1609). The company has garnered recognition, including winning an American Diabetes Association Innovation Challenge, and is building a strong advisory and leadership team with expertise in translation and drug development.

Therapeutic Areas